Clinical Board Chairman
PCaVision combines multiparametric ultrasound imaging with AI-powered algorithms to detect suspicious areas for prostate cancer. Facilitating diagnosis for urologists, without the need for MRI.
Instant 3D visualization of suspicious PCa regions.
Our Clinical Partners
How does PCaVision work?
Full facilitation of the diagnostic process for urologist
Relies on PCaVision clinically validated performance, no MRI in the pathway.
Streamlined clinical pathway
From multi-department visits to potentially 1 urology-led visit.
Optimal care pathway for patients
Faster decision-making, negative patients receive results in minutes instead of waiting multiple weeks in the MRI pathway.
Bridge the diagnostic capacity gap
As demand rises and MRI capacity remains constrained, PCaVision provides a scalable alternative.
Facilitates optimized diagnostic pathway for everyone
Urologists
- Full clinical control over the patient pathway
- Simplified, optimised diagnostic process
- Low variability through AI interpretation
- Targeted biopsies during the first consultation
Patients
- Faster diagnosis and treatment
- Fewer consultations and less travelling
- Less invasive diagnostic approach
- Immediate relief – results in the same visit
Clinics & Hospitals
- Increased patient access and throughput
- High-quality, scalable PCa diagnostic pathway
- Frees up scarce MRI capacity for other care
- Positive business case
Regulatory approved. Commercially deployed.
Regulatory approved
CE/MDR Class IIb Certified
- ISO 13485 Quality Management certified
- Available in authorized EU markets
Commercially Deployed
First clinical adopters
- Amsterdam UMC – Clinical Partner
- First Academic hospital in The Netherlands
- First private clinic in Germany
Trusted by leading clinical and scientific experts
Science is fascinating; its translation into solutions helping cancer patients is a real mission
Scientific Strategic Advisor
Latest news
EAU26 was great!
It was a pleasure connecting with so many urologists and professionals committed to advancing prostate cancer diagnosis. A standout moment was the presentation “Artificial intelligence-assisted multiparametric ultrasound versus MRI to…
Read more → 
Successful crowdfunding!
PCaVision’s INVESDOR crowdfunding is now successfully closed at €2,826,137 invested by 449 investors. A big thank you to all investors who joined our mission to make prostate cancer diagnosis fast, accurate…
Read more →